Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/Synthetic Blood

Executive Summary

Abbott acquired 5% of Synthetic Blood's equity with the right to increase its equity position to 20% over the next eight months. Chicago-based Quixote Corp., a founding shareholder of Synthetic Blood, currently owns approximately 29% of the company and said it will invest more money in Synthetic Blood as Abbott increases its ownership to 20%. Synthetic Blood is developing a coacervate preparation as a possible substitute for whole blood. Quixote said Abbott and Synthetic Blood have an understanding "which may lead to further agreements with respect to the manufacture and marketing of Synthetic Blood products and drug delivery systems".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel